
July 21 (Reuters) - Oruka Therapeutics Inc ORKA.O:
ORUKA THERAPEUTICS ANNOUNCES IND CLEARANCE FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN PSORIASIS WITH PHASE 1 DATA TO BE PRESENTED AT EADV IN SEPTEMBER
ORUKA THERAPEUTICS: IND CLEARED FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN MODERATE-TO-SEVERE PSORIASIS, WITH INITIAL DATA EXPECTED 2H 2026